The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis.
The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis.
复制标题
DOI：
10.1186/s12885-020-07622-6
复制
发表时间：
2020-11-19
期刊：
影响因子：
3.8
通讯作者：
Shi Q
中科院分区：
文献类型：
--
作者：
Chai M;Shi Q
肺结核（TB）和肺癌有着复杂的关系。关于肺癌患者结核病治疗的数据仍然不完整。本研究的目的是探讨肺癌合并活动性肺结核患者的抗癌和抗结核治疗的效果。在一项回顾性队列研究中，在2013年1月至2016年12月期间确定了活动性肺结核的肺癌患者。年龄和性别相匹配的非结核性肺癌患者被选为对照组。抗癌和抗结核治疗按照国家指导方针进行。对有无活动性肺结核的肺癌患者的临床病程和反应进行了检查和比较。共有31名连续肺癌患者被诊断为活动性肺结核。51例非结核性肺癌患者作为对照组。两组中的大多数患者都是老年人，患有晚期非小细胞肺癌，并且有肿瘤负荷。两组患者的抗肿瘤治疗完成率和有效率无差异（分别为87.1%和92.2%，结核治疗患者77.4%和88.2%）。抗结核治疗完成率和成功率分别为87.1%和80.7%。两组之间的中位生存时间没有差异（结核病治疗患者为52周，肺癌患者为57周）。Karnofsky评分的变化在两组之间也没有差异。肺结核治疗中最常见的副作用是肝损害（61.3%）。结核病治疗患者中最严重的副作用是白细胞减少（3级为9.7%）。上述两种不良反应两组间无差异。抗癌和抗结核治疗都可以安全有效地应用于活动性肺结核的肺癌患者。应关注结核病高负担国家肺癌患者的结核病风险。
Lung tuberculosis (TB) and lung cancer have a complex relationship. Data concerning TB treatment in lung cancer patients are still incomplete. The aim of this study was to investigate the effects of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active lung TB. In a retrospective cohort study, lung cancer patients with active lung TB were identified between January 2013 and December 2016. Age- and sex-matched lung cancer patients without tuberculosis were selected as control subjects. Anti-cancer and anti-tuberculosis treatments were administered according to the national guidelines. The clinical courses and responses of lung cancer patients with and without active lung TB were examined and compared. A total of 31 consecutive lung cancer patients were diagnosed with active lung TB. Fifty-one lung cancer patients without TB were enrolled as control subjects. Most patients in the two groups were elderly, had advanced non-small cell lung cancer and had tumor burdens. The anti-cancer treatment completion rate and response rate were not different between two group (87.1% in TB treatment patients vs. 92.2% in lung cancer patients, 77.4% in TB treatment patients vs. 88.2% in lung cancer patients, respectively). The anti-tuberculosis treatment completion rate and success rate was 87.1 and 80.7%. The median survival times were not different between two groups (52 weeks in TB treatment patients vs. 57 weeks in lung cancer patients). The change in Karnofsky performance score was also not different between two groups. The most common side effect in TB treatment patients was liver injury (61.3%). The most serious side effect in TB treatment patients was leukocyte deficiency (9.7% in Grade 3). Both of side effects mentioned above were not different between two groups. Both anti-cancer and anti-tuberculosis treatments can be safely and effectively administered in lung cancer patients with active lung TB. Attention should be paid to the risk of tuberculosis in lung cancer patients in TB high-burden countries.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
1
作者：
Islam, Tauhid;Hiatt, Tom;Nishikiori, Nobuyuki
通讯作者：
Nishikiori, Nobuyuki
影响因子：
2.9
作者：
Fan H;Shao ZY;Xiao YY;Xie ZH;Chen W;Xie H;Qin GY;Zhao NQ
通讯作者：
Zhao NQ
影响因子：
8.4
作者：
Cui, Xiaojing;Gao, Lei;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
17.1
作者：
Barber, Daniel L.;Sakai, Shunsuke;Sharon, Elad
通讯作者：
Sharon, Elad